Drugs / CD19-targeted CAR-T cells
CD19-targeted CAR-T cells
also known as
Autologous CD19 CAR-T cells · CAR-CD19-modified T cells · CD19 CAR T cells · CD19 CAR-T Cell Therapy · CD19 CART cell · CD19.CAR-T · GoFast CD19 CAR T cells
Cell therapy targets CD19 via depletion
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07670260 | Jun 2026 → Sep 2027 expected | large B-cell lymphoma | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06056921 | Aug 2023 → Dec 2025 overdue | Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, dermatomyositis, systemic lupus erythematosus +1 | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT03599375 | May 2019 → Dec 2020 | B-cell acute lymphoblastic leukemia | jiuwei cui | Unknown | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07681388 | Jan → Dec 2026 expected | pemphigus vulgaris | Jinbo Chen | Recruiting | No outcome recorded |
| — | NCT03564977 | Jul 2018 → Jun 2020 | B-cell non-Hodgkin lymphoma, lymphoid leukemia | Qingdao Central Hospital | Unknown | No outcome recorded |
| — | NCT03488160 | Apr 2018 → Apr 2019 | lymphoma | Sinobioway Cell Therapy Co., Ltd. | Unknown | No outcome recorded |
| — | NCT02735291 | Nov 2015 → Dec 2019 | leukemia | Sinobioway Cell Therapy Co., Ltd. | Unknown | No outcome recorded |
| — | NCT02728882 | Jul 2015 → Jul 2019 | lymphoma | Sinobioway Cell Therapy Co., Ltd. | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07613788 Background | May 2026 → Nov 2028 expected | large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-targeted CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03488160 ↗ |
| Known as | Autologous CD19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07681388 ↗ |
| Known as | CAR-CD19-modified T cells | “Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor...” NCT03488160 ↗ |
| Known as | CD19 CAR T cells | “CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv.” NCT03599375 ↗ |
| Known as | CD19 CAR-T Cell Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07613788 ↗ |
| Known as | CD19 CART cell | “for the generation of the CD19 CART cell and administered by i.v. injection.” NCT03599375 ↗ |
| Known as | CD19.CAR-T | “The safety and feasibility of CAR-T cells (CD19.CAR-T) targeted at CD19 in the treatment of relapsed / refractory CD19 positive lymphoma were determined, and the proliferation...” NCT03488160 ↗ |
| Known as | GoFast CD19 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07670260 ↗ |
| Action | Deplete | “the CAR-CD19-modified T cells can recognize and kill tumor cells in the body” NCT02728882 ↗ |
| Modality | Cell therapy | “infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor (CAR)” NCT02728882 ↗ |
| Route | Intravenous | “administered by i.v. injection” NCT03599375 ↗ |
| Target | CD19 | “CD19-targeted CAR-T cells” NCT02728882 ↗ |